![\"\"](\"https:\/\/www.merckvaccines.com\/vaqta\/wp-content\/uploads\/sites\/163\/2026\/03\/VAQTA_FAQ_Banner_1128px.svg?w=1488\")
<\/picture>Frequently asked questions about VAQTA\u00ae (Hepatitis A Vaccine, Inactivated)<\/strong><\/strong><\/h1><\/p>
\n\n<\/p>\n\n<\/div>
<\/div><\/div><\/div><\/div><\/div><\/div>\n\n\n\n<\/p>\n\n\n\n
<\/div>\n\n\n\n\ndefault-sum-open-background-color<\/div>default-sum-close-background-color<\/div>false<\/div>default-sum-open-hover-color<\/div>default-sum-open-focus-color<\/div>default-sum-close-focus-color<\/div>.default-sum-close-hover-color<\/div>What is the indication and usage for VAQTA?<\/h4><\/summary>\n<\/div>\n\n\n\nVAQTA is indicated for the prevention of disease caused by hepatitis A virus in persons 12 months of age and older. The primary dose should be given at least 2 weeks prior to expected exposure to HAV.<\/p>\n\n\n\n
<\/div>\n<\/div><\/details><\/div>\n\n\n\ndefault-sum-open-background-color<\/div>default-sum-close-background-color<\/div>false<\/div>default-sum-open-hover-color<\/div>default-sum-open-focus-color<\/div>default-sum-close-focus-color<\/div>.default-sum-close-hover-color<\/div>What is the dosing for VAQTA?<\/h4><\/summary>\n<\/div>\n\n\n\nFor children and adolescents 12 months through 18 years of age, vaccination with VAQTA consists of a 0.5-mL primary dose administered intramuscularly and a 0.5-mL booster dose administered intramuscularly 6 to 18 months later.<\/p>\n\n\n\n
<\/div>\n\n\n\nFor adults 19 years of age and older, vaccination with VAQTA consists of a 1-mL primary dose administered intramuscularly and a 1-mL booster dose administered intramuscularly 6 to 18 months later.<\/p>\n\n\n\n
<\/div>\n\n\n\nView dosing and adminstration<\/a><\/strong><\/p>\n\n\n\n<\/div>\n<\/div><\/details><\/div>\n\n\n\ndefault-sum-open-background-color<\/div>default-sum-close-background-color<\/div>false<\/div>default-sum-open-hover-color<\/div>default-sum-open-focus-color<\/div>default-sum-close-focus-color<\/div>.default-sum-close-hover-color<\/div>What is the Select Safety Information for VAQTA?<\/h4><\/summary>\n<\/div>\n\n\n\nDo not administer VAQTA to individuals with a history of immediate and\/or severe allergic or hypersensitivity reactions (eg, anaphylaxis) after a previous dose of any hepatitis A vaccine, or to individuals who have had an anaphylactic reaction to any component of VAQTA, including neomycin.<\/p>\n\n\n\n
<\/div>\n\n\n\nThe vial stopper contains dry natural latex rubber that may cause allergic reactions in latex-sensitive individuals.<\/p>\n\n\n\n
<\/div>\n\n\n\nThe most common local adverse reactions and systemic adverse events (\u226515%) reported in different clinical trials across different age groups when VAQTA was administered alone or concomitantly were:<\/p>\n\n\n\n
<\/div>\n\n\n\n\n\n\n- Children 12 through 23 months of age: injection-site pain\/tenderness (37.0%), injection-site erythema (21.2%), and fever (16.4% when administered alone, and 27.0% when administered concomitantly).<\/li>\n\n\n\n
- Children\/Adolescents 2 through 18 years of age: injection-site pain (18.7%).<\/li>\n\n\n\n
- Adults 19 years of age and older: injection-site pain, tenderness, or soreness (67.0%), injection site warmth (18.2%), and headache (16.1%).<\/li>\n<\/ul>\n<\/div>\n\n\n\n<\/div>\n\n\n\n
Safety and effectiveness in infants below 12 months of age have not been established.<\/p><\/div><\/div><\/p>\n\n\n\n
<\/div>\n\n\n\nImmunocompromised persons, including individuals receiving immunosuppressive therapy, may have a diminished immune response to VAQTA and may not be protected against HAV infection after vaccination.<\/p><\/div><\/div><\/p>\n\n\n\n
<\/div>\n\n\n\nHepatitis A virus has a relatively long incubation period (approximately 20 to 50 days). VAQTA may not prevent hepatitis A infection in individuals who have an unrecognized hepatitis A infection at the time of vaccination.<\/p><\/div><\/div><\/p>\n\n\n\n
<\/div>\n\n\n\nIn clinical trials in children, VAQTA was concomitantly administered with one or more of the following US-licensed vaccines: Measles, Mumps, and Rubella Virus Vaccine, Live; Varicella Vaccine, Live; Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine, Adsorbed; Measles, Mumps, Rubella, and Varicella Vaccine, Live; Pneumococcal 7-valent Conjugate Vaccine; and Haemophilus b Conjugate Vaccine (Meningococcal Protein Conjugate). Safety and immunogenicity were similar for concomitantly administered vaccines compared to separately administered vaccines.<\/p><\/div><\/div><\/p>\n\n\n\n
<\/div>\n\n\n\nIn clinical trials in adults, VAQTA was concomitantly administered with typhoid Vi polysaccharide and yellow fever vaccines. Safety and immunogenicity were similar for concomitantly administered vaccines compared to separately administered vaccines.<\/p>\n\n\n\n
<\/div>\n\n\n\nVAQTA may be administered concomitantly with Immune Globulin, human, using separate sites and syringes.<\/p><\/div><\/div><\/p>\n\n\n\n
<\/div>\n\n\n\nThere are no adequate and well-controlled studies designed to evaluate VAQTA in pregnant women, including those 19 years of age or younger. Available post-approval data do not suggest an increased risk of miscarriage or major birth defects in women who received VAQTA during pregnancy.<\/p><\/div><\/div><\/p>\n\n\n\n
<\/div>\n\n\n\nIt is not known whether VAQTA is excreted in human milk. Data are not available to assess the effects of VAQTA on the breastfed infant or on milk production\/excretion. The developmental and health benefits of breastfeeding should be considered along with the mother\u2019s clinical need for VAQTA and any potential adverse effects on the breastfed child from VAQTA or from the underlying maternal condition.<\/p><\/div><\/div><\/p>\n\n\n\n
<\/div>\n\n\n\nThe total duration of the protective effect of VAQTA in healthy vaccinees is unknown at present.<\/p><\/div><\/div><\/p>\n\n\n\n
<\/div>\n\n\n\nVaccination with VAQTA may not result in a protective response in all susceptible vaccinees.<\/p><\/div><\/div><\/p>\n\n\n\n
<\/div>\n\n\n\nBefore administering VAQTA, please read the accompanying Prescribing Information<\/a>. The Patient Information<\/a> also is available.<\/strong><\/p>\n<\/div><\/details><\/div>\n\n\n\ndefault-sum-open-background-color<\/div>default-sum-close-background-color<\/div>false<\/div>default-sum-open-hover-color<\/div>default-sum-open-focus-color<\/div>default-sum-close-focus-color<\/div>.default-sum-close-hover-color<\/div>How is VAQTA administered?<\/h4><\/summary>\n<\/div>\n\n\n\nVAQTA is administered intramuscularly. The deltoid muscle is the preferred site of intramuscular administration in adults, adolescents, and children older than 2 years of age. The anterolateral area of the thigh is the preferred site for children 12 through 23 months of age.<\/p>\n\n\n\n
<\/div>\n<\/div><\/details><\/div>\n\n\n\ndefault-sum-open-background-color<\/div>default-sum-close-background-color<\/div>false<\/div>default-sum-open-hover-color<\/div>default-sum-open-focus-color<\/div>default-sum-close-focus-color<\/div>.default-sum-close-hover-color<\/div>Can VAQTA be given following a first dose of Havrix<\/em>*?<\/h4><\/summary>\n<\/div>\n\n\n\nYes, a booster dose of VAQTA may be given at 6 to 12 months following a primary dose of Havrix<\/em>*.<\/p>\n\n\n\n<\/div>\n\n\n\n*Havrix is a registered trademark of GSK.<\/em><\/p>\n\n\n\n<\/div>\n<\/div><\/details><\/div>\n\n\n\ndefault-sum-open-background-color<\/div>default-sum-close-background-color<\/div>false<\/div>default-sum-open-hover-color<\/div>default-sum-open-focus-color<\/div>default-sum-close-focus-color<\/div>.default-sum-close-hover-color<\/div>What was the immune response of VAQTA in adults when VAQTA is given as the second dose following a first dose with another brand?<\/h4><\/summary>\n<\/div>\n\n\n\n
<\/p>\n\n<\/div>
<\/p>\n\n\n\n
What is the indication and usage for VAQTA?<\/h4><\/summary>\n<\/div>\n\n\n\nVAQTA is indicated for the prevention of disease caused by hepatitis A virus in persons 12 months of age and older. The primary dose should be given at least 2 weeks prior to expected exposure to HAV.<\/p>\n\n\n\n
<\/div>\n<\/div><\/details><\/div>\n\n\n\ndefault-sum-open-background-color<\/div>default-sum-close-background-color<\/div>false<\/div>default-sum-open-hover-color<\/div>default-sum-open-focus-color<\/div>default-sum-close-focus-color<\/div>.default-sum-close-hover-color<\/div>What is the dosing for VAQTA?<\/h4><\/summary>\n<\/div>\n\n\n\nFor children and adolescents 12 months through 18 years of age, vaccination with VAQTA consists of a 0.5-mL primary dose administered intramuscularly and a 0.5-mL booster dose administered intramuscularly 6 to 18 months later.<\/p>\n\n\n\n
<\/div>\n\n\n\nFor adults 19 years of age and older, vaccination with VAQTA consists of a 1-mL primary dose administered intramuscularly and a 1-mL booster dose administered intramuscularly 6 to 18 months later.<\/p>\n\n\n\n
<\/div>\n\n\n\nView dosing and adminstration<\/a><\/strong><\/p>\n\n\n\n<\/div>\n<\/div><\/details><\/div>\n\n\n\ndefault-sum-open-background-color<\/div>default-sum-close-background-color<\/div>false<\/div>default-sum-open-hover-color<\/div>default-sum-open-focus-color<\/div>default-sum-close-focus-color<\/div>.default-sum-close-hover-color<\/div>What is the Select Safety Information for VAQTA?<\/h4><\/summary>\n<\/div>\n\n\n\nDo not administer VAQTA to individuals with a history of immediate and\/or severe allergic or hypersensitivity reactions (eg, anaphylaxis) after a previous dose of any hepatitis A vaccine, or to individuals who have had an anaphylactic reaction to any component of VAQTA, including neomycin.<\/p>\n\n\n\n
<\/div>\n\n\n\nThe vial stopper contains dry natural latex rubber that may cause allergic reactions in latex-sensitive individuals.<\/p>\n\n\n\n
<\/div>\n\n\n\nThe most common local adverse reactions and systemic adverse events (\u226515%) reported in different clinical trials across different age groups when VAQTA was administered alone or concomitantly were:<\/p>\n\n\n\n
<\/div>\n\n\n\n\n\n\n- Children 12 through 23 months of age: injection-site pain\/tenderness (37.0%), injection-site erythema (21.2%), and fever (16.4% when administered alone, and 27.0% when administered concomitantly).<\/li>\n\n\n\n
- Children\/Adolescents 2 through 18 years of age: injection-site pain (18.7%).<\/li>\n\n\n\n
- Adults 19 years of age and older: injection-site pain, tenderness, or soreness (67.0%), injection site warmth (18.2%), and headache (16.1%).<\/li>\n<\/ul>\n<\/div>\n\n\n\n<\/div>\n\n\n\n
Safety and effectiveness in infants below 12 months of age have not been established.<\/p><\/div><\/div><\/p>\n\n\n\n
<\/div>\n\n\n\nImmunocompromised persons, including individuals receiving immunosuppressive therapy, may have a diminished immune response to VAQTA and may not be protected against HAV infection after vaccination.<\/p><\/div><\/div><\/p>\n\n\n\n
<\/div>\n\n\n\nHepatitis A virus has a relatively long incubation period (approximately 20 to 50 days). VAQTA may not prevent hepatitis A infection in individuals who have an unrecognized hepatitis A infection at the time of vaccination.<\/p><\/div><\/div><\/p>\n\n\n\n
<\/div>\n\n\n\nIn clinical trials in children, VAQTA was concomitantly administered with one or more of the following US-licensed vaccines: Measles, Mumps, and Rubella Virus Vaccine, Live; Varicella Vaccine, Live; Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine, Adsorbed; Measles, Mumps, Rubella, and Varicella Vaccine, Live; Pneumococcal 7-valent Conjugate Vaccine; and Haemophilus b Conjugate Vaccine (Meningococcal Protein Conjugate). Safety and immunogenicity were similar for concomitantly administered vaccines compared to separately administered vaccines.<\/p><\/div><\/div><\/p>\n\n\n\n
<\/div>\n\n\n\nIn clinical trials in adults, VAQTA was concomitantly administered with typhoid Vi polysaccharide and yellow fever vaccines. Safety and immunogenicity were similar for concomitantly administered vaccines compared to separately administered vaccines.<\/p>\n\n\n\n
<\/div>\n\n\n\nVAQTA may be administered concomitantly with Immune Globulin, human, using separate sites and syringes.<\/p><\/div><\/div><\/p>\n\n\n\n
<\/div>\n\n\n\nThere are no adequate and well-controlled studies designed to evaluate VAQTA in pregnant women, including those 19 years of age or younger. Available post-approval data do not suggest an increased risk of miscarriage or major birth defects in women who received VAQTA during pregnancy.<\/p><\/div><\/div><\/p>\n\n\n\n
<\/div>\n\n\n\nIt is not known whether VAQTA is excreted in human milk. Data are not available to assess the effects of VAQTA on the breastfed infant or on milk production\/excretion. The developmental and health benefits of breastfeeding should be considered along with the mother\u2019s clinical need for VAQTA and any potential adverse effects on the breastfed child from VAQTA or from the underlying maternal condition.<\/p><\/div><\/div><\/p>\n\n\n\n
<\/div>\n\n\n\nThe total duration of the protective effect of VAQTA in healthy vaccinees is unknown at present.<\/p><\/div><\/div><\/p>\n\n\n\n
<\/div>\n\n\n\nVaccination with VAQTA may not result in a protective response in all susceptible vaccinees.<\/p><\/div><\/div><\/p>\n\n\n\n
<\/div>\n\n\n\nBefore administering VAQTA, please read the accompanying Prescribing Information<\/a>. The Patient Information<\/a> also is available.<\/strong><\/p>\n<\/div><\/details><\/div>\n\n\n\ndefault-sum-open-background-color<\/div>default-sum-close-background-color<\/div>false<\/div>default-sum-open-hover-color<\/div>default-sum-open-focus-color<\/div>default-sum-close-focus-color<\/div>.default-sum-close-hover-color<\/div>How is VAQTA administered?<\/h4><\/summary>\n<\/div>\n\n\n\nVAQTA is administered intramuscularly. The deltoid muscle is the preferred site of intramuscular administration in adults, adolescents, and children older than 2 years of age. The anterolateral area of the thigh is the preferred site for children 12 through 23 months of age.<\/p>\n\n\n\n
<\/div>\n<\/div><\/details><\/div>\n\n\n\ndefault-sum-open-background-color<\/div>default-sum-close-background-color<\/div>false<\/div>default-sum-open-hover-color<\/div>default-sum-open-focus-color<\/div>default-sum-close-focus-color<\/div>.default-sum-close-hover-color<\/div>Can VAQTA be given following a first dose of Havrix<\/em>*?<\/h4><\/summary>\n<\/div>\n\n\n\nYes, a booster dose of VAQTA may be given at 6 to 12 months following a primary dose of Havrix<\/em>*.<\/p>\n\n\n\n<\/div>\n\n\n\n*Havrix is a registered trademark of GSK.<\/em><\/p>\n\n\n\n<\/div>\n<\/div><\/details><\/div>\n\n\n\ndefault-sum-open-background-color<\/div>default-sum-close-background-color<\/div>false<\/div>default-sum-open-hover-color<\/div>default-sum-open-focus-color<\/div>default-sum-close-focus-color<\/div>.default-sum-close-hover-color<\/div>What was the immune response of VAQTA in adults when VAQTA is given as the second dose following a first dose with another brand?<\/h4><\/summary>\n<\/div>\n\n\n\n
VAQTA is indicated for the prevention of disease caused by hepatitis A virus in persons 12 months of age and older. The primary dose should be given at least 2 weeks prior to expected exposure to HAV.<\/p>\n\n\n\n
What is the dosing for VAQTA?<\/h4><\/summary>\n<\/div>\n\n\n\nFor children and adolescents 12 months through 18 years of age, vaccination with VAQTA consists of a 0.5-mL primary dose administered intramuscularly and a 0.5-mL booster dose administered intramuscularly 6 to 18 months later.<\/p>\n\n\n\n
<\/div>\n\n\n\nFor adults 19 years of age and older, vaccination with VAQTA consists of a 1-mL primary dose administered intramuscularly and a 1-mL booster dose administered intramuscularly 6 to 18 months later.<\/p>\n\n\n\n
<\/div>\n\n\n\nView dosing and adminstration<\/a><\/strong><\/p>\n\n\n\n<\/div>\n<\/div><\/details><\/div>\n\n\n\ndefault-sum-open-background-color<\/div>default-sum-close-background-color<\/div>false<\/div>default-sum-open-hover-color<\/div>default-sum-open-focus-color<\/div>default-sum-close-focus-color<\/div>.default-sum-close-hover-color<\/div>What is the Select Safety Information for VAQTA?<\/h4><\/summary>\n<\/div>\n\n\n\nDo not administer VAQTA to individuals with a history of immediate and\/or severe allergic or hypersensitivity reactions (eg, anaphylaxis) after a previous dose of any hepatitis A vaccine, or to individuals who have had an anaphylactic reaction to any component of VAQTA, including neomycin.<\/p>\n\n\n\n
<\/div>\n\n\n\nThe vial stopper contains dry natural latex rubber that may cause allergic reactions in latex-sensitive individuals.<\/p>\n\n\n\n
<\/div>\n\n\n\nThe most common local adverse reactions and systemic adverse events (\u226515%) reported in different clinical trials across different age groups when VAQTA was administered alone or concomitantly were:<\/p>\n\n\n\n
<\/div>\n\n\n\n\n\n\n- Children 12 through 23 months of age: injection-site pain\/tenderness (37.0%), injection-site erythema (21.2%), and fever (16.4% when administered alone, and 27.0% when administered concomitantly).<\/li>\n\n\n\n
- Children\/Adolescents 2 through 18 years of age: injection-site pain (18.7%).<\/li>\n\n\n\n
- Adults 19 years of age and older: injection-site pain, tenderness, or soreness (67.0%), injection site warmth (18.2%), and headache (16.1%).<\/li>\n<\/ul>\n<\/div>\n\n\n\n<\/div>\n\n\n\n
Safety and effectiveness in infants below 12 months of age have not been established.<\/p><\/div><\/div><\/p>\n\n\n\n
<\/div>\n\n\n\nImmunocompromised persons, including individuals receiving immunosuppressive therapy, may have a diminished immune response to VAQTA and may not be protected against HAV infection after vaccination.<\/p><\/div><\/div><\/p>\n\n\n\n
<\/div>\n\n\n\nHepatitis A virus has a relatively long incubation period (approximately 20 to 50 days). VAQTA may not prevent hepatitis A infection in individuals who have an unrecognized hepatitis A infection at the time of vaccination.<\/p><\/div><\/div><\/p>\n\n\n\n
<\/div>\n\n\n\nIn clinical trials in children, VAQTA was concomitantly administered with one or more of the following US-licensed vaccines: Measles, Mumps, and Rubella Virus Vaccine, Live; Varicella Vaccine, Live; Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine, Adsorbed; Measles, Mumps, Rubella, and Varicella Vaccine, Live; Pneumococcal 7-valent Conjugate Vaccine; and Haemophilus b Conjugate Vaccine (Meningococcal Protein Conjugate). Safety and immunogenicity were similar for concomitantly administered vaccines compared to separately administered vaccines.<\/p><\/div><\/div><\/p>\n\n\n\n
<\/div>\n\n\n\nIn clinical trials in adults, VAQTA was concomitantly administered with typhoid Vi polysaccharide and yellow fever vaccines. Safety and immunogenicity were similar for concomitantly administered vaccines compared to separately administered vaccines.<\/p>\n\n\n\n
<\/div>\n\n\n\nVAQTA may be administered concomitantly with Immune Globulin, human, using separate sites and syringes.<\/p><\/div><\/div><\/p>\n\n\n\n
<\/div>\n\n\n\nThere are no adequate and well-controlled studies designed to evaluate VAQTA in pregnant women, including those 19 years of age or younger. Available post-approval data do not suggest an increased risk of miscarriage or major birth defects in women who received VAQTA during pregnancy.<\/p><\/div><\/div><\/p>\n\n\n\n
<\/div>\n\n\n\nIt is not known whether VAQTA is excreted in human milk. Data are not available to assess the effects of VAQTA on the breastfed infant or on milk production\/excretion. The developmental and health benefits of breastfeeding should be considered along with the mother\u2019s clinical need for VAQTA and any potential adverse effects on the breastfed child from VAQTA or from the underlying maternal condition.<\/p><\/div><\/div><\/p>\n\n\n\n
<\/div>\n\n\n\nThe total duration of the protective effect of VAQTA in healthy vaccinees is unknown at present.<\/p><\/div><\/div><\/p>\n\n\n\n
<\/div>\n\n\n\nVaccination with VAQTA may not result in a protective response in all susceptible vaccinees.<\/p><\/div><\/div><\/p>\n\n\n\n
<\/div>\n\n\n\nBefore administering VAQTA, please read the accompanying Prescribing Information<\/a>. The Patient Information<\/a> also is available.<\/strong><\/p>\n<\/div><\/details><\/div>\n\n\n\ndefault-sum-open-background-color<\/div>default-sum-close-background-color<\/div>false<\/div>default-sum-open-hover-color<\/div>default-sum-open-focus-color<\/div>default-sum-close-focus-color<\/div>.default-sum-close-hover-color<\/div>How is VAQTA administered?<\/h4><\/summary>\n<\/div>\n\n\n\nVAQTA is administered intramuscularly. The deltoid muscle is the preferred site of intramuscular administration in adults, adolescents, and children older than 2 years of age. The anterolateral area of the thigh is the preferred site for children 12 through 23 months of age.<\/p>\n\n\n\n
<\/div>\n<\/div><\/details><\/div>\n\n\n\ndefault-sum-open-background-color<\/div>default-sum-close-background-color<\/div>false<\/div>default-sum-open-hover-color<\/div>default-sum-open-focus-color<\/div>default-sum-close-focus-color<\/div>.default-sum-close-hover-color<\/div>Can VAQTA be given following a first dose of Havrix<\/em>*?<\/h4><\/summary>\n<\/div>\n\n\n\nYes, a booster dose of VAQTA may be given at 6 to 12 months following a primary dose of Havrix<\/em>*.<\/p>\n\n\n\n<\/div>\n\n\n\n*Havrix is a registered trademark of GSK.<\/em><\/p>\n\n\n\n<\/div>\n<\/div><\/details><\/div>\n\n\n\ndefault-sum-open-background-color<\/div>default-sum-close-background-color<\/div>false<\/div>default-sum-open-hover-color<\/div>default-sum-open-focus-color<\/div>default-sum-close-focus-color<\/div>.default-sum-close-hover-color<\/div>What was the immune response of VAQTA in adults when VAQTA is given as the second dose following a first dose with another brand?<\/h4><\/summary>\n<\/div>\n\n\n\n
For children and adolescents 12 months through 18 years of age, vaccination with VAQTA consists of a 0.5-mL primary dose administered intramuscularly and a 0.5-mL booster dose administered intramuscularly 6 to 18 months later.<\/p>\n\n\n\n
For adults 19 years of age and older, vaccination with VAQTA consists of a 1-mL primary dose administered intramuscularly and a 1-mL booster dose administered intramuscularly 6 to 18 months later.<\/p>\n\n\n\n
View dosing and adminstration<\/a><\/strong><\/p>\n\n\n\n Do not administer VAQTA to individuals with a history of immediate and\/or severe allergic or hypersensitivity reactions (eg, anaphylaxis) after a previous dose of any hepatitis A vaccine, or to individuals who have had an anaphylactic reaction to any component of VAQTA, including neomycin.<\/p>\n\n\n\n The vial stopper contains dry natural latex rubber that may cause allergic reactions in latex-sensitive individuals.<\/p>\n\n\n\n The most common local adverse reactions and systemic adverse events (\u226515%) reported in different clinical trials across different age groups when VAQTA was administered alone or concomitantly were:<\/p>\n\n\n\n Safety and effectiveness in infants below 12 months of age have not been established.<\/p><\/div><\/div><\/p>\n\n\n\n Immunocompromised persons, including individuals receiving immunosuppressive therapy, may have a diminished immune response to VAQTA and may not be protected against HAV infection after vaccination.<\/p><\/div><\/div><\/p>\n\n\n\n Hepatitis A virus has a relatively long incubation period (approximately 20 to 50 days). VAQTA may not prevent hepatitis A infection in individuals who have an unrecognized hepatitis A infection at the time of vaccination.<\/p><\/div><\/div><\/p>\n\n\n\n In clinical trials in children, VAQTA was concomitantly administered with one or more of the following US-licensed vaccines: Measles, Mumps, and Rubella Virus Vaccine, Live; Varicella Vaccine, Live; Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine, Adsorbed; Measles, Mumps, Rubella, and Varicella Vaccine, Live; Pneumococcal 7-valent Conjugate Vaccine; and Haemophilus b Conjugate Vaccine (Meningococcal Protein Conjugate). Safety and immunogenicity were similar for concomitantly administered vaccines compared to separately administered vaccines.<\/p><\/div><\/div><\/p>\n\n\n\n In clinical trials in adults, VAQTA was concomitantly administered with typhoid Vi polysaccharide and yellow fever vaccines. Safety and immunogenicity were similar for concomitantly administered vaccines compared to separately administered vaccines.<\/p>\n\n\n\n VAQTA may be administered concomitantly with Immune Globulin, human, using separate sites and syringes.<\/p><\/div><\/div><\/p>\n\n\n\n There are no adequate and well-controlled studies designed to evaluate VAQTA in pregnant women, including those 19 years of age or younger. Available post-approval data do not suggest an increased risk of miscarriage or major birth defects in women who received VAQTA during pregnancy.<\/p><\/div><\/div><\/p>\n\n\n\n It is not known whether VAQTA is excreted in human milk. Data are not available to assess the effects of VAQTA on the breastfed infant or on milk production\/excretion. The developmental and health benefits of breastfeeding should be considered along with the mother\u2019s clinical need for VAQTA and any potential adverse effects on the breastfed child from VAQTA or from the underlying maternal condition.<\/p><\/div><\/div><\/p>\n\n\n\n The total duration of the protective effect of VAQTA in healthy vaccinees is unknown at present.<\/p><\/div><\/div><\/p>\n\n\n\n Vaccination with VAQTA may not result in a protective response in all susceptible vaccinees.<\/p><\/div><\/div><\/p>\n\n\n\n Before administering VAQTA, please read the accompanying Prescribing Information<\/a>. The Patient Information<\/a> also is available.<\/strong><\/p>\n<\/div><\/details><\/div>\n\n\n\n VAQTA is administered intramuscularly. The deltoid muscle is the preferred site of intramuscular administration in adults, adolescents, and children older than 2 years of age. The anterolateral area of the thigh is the preferred site for children 12 through 23 months of age.<\/p>\n\n\n\n Yes, a booster dose of VAQTA may be given at 6 to 12 months following a primary dose of Havrix<\/em>*.<\/p>\n\n\n\n *Havrix is a registered trademark of GSK.<\/em><\/p>\n\n\n\nWhat is the Select Safety Information for VAQTA?<\/h4><\/summary>
\n
How is VAQTA administered?<\/h4><\/summary>
Can VAQTA be given following a first dose of Havrix<\/em>*?<\/h4><\/summary>
What was the immune response of VAQTA in adults when VAQTA is given as the second dose following a first dose with another brand?<\/h4><\/summary>